ReviewMolecular diagnosis & therapy2020

Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Pedro Renato de Paula Brandão et al.PubMed ↗Publisher ↗

No numbers read from the abstract.